Abstract:KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene in human pancreatic cancer (∼95% of cases). Mutations in KRAS lead to its constitutive activation and activation of its downstream signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR that promote cell proliferation and provide apoptosis evasion capabilities to cancer cells. KRAS had been considered 'undruggable' until the discovery of the first covalent inhibitor targeting the G12C mutation. While G12C mutations are frequently found in non-small cell lung cancer, these are relatively rare in pancreatic cancer. On the other hand, pancreatic cancer harbors other KRAS mutations such as G12D and G12V. The inhibitors targeting G12D mutation (such as MRTX1133) have been recently developed, whereas those targeting other mutations are still lacking. Unfortunately, KRAS inhibitor monotherapy-associated resistance hinders their therapeutic efficacy. Therefore, various combination strategies have been tested and some yielded promising results, such as combinations with receptor tyrosine kinase, SHP2, or SOS1 inhibitors. In addition, we recently demonstrated that the combination of sotorasib with DT2216 (a BCL-XL-selective degrader) synergistically inhibits G12C-mutated pancreatic cancer cell growth in vitro and in vivo. This is in part because KRAS-targeted therapies induce cell cycle arrest and cellular senescence, which contributes to therapeutic resistance, while their combination with DT2216 can more effectively induce apoptosis. Similar combination strategies may also work for G12D inhibitors in pancreatic cancer. This chapter will review KRAS biochemistry, signaling pathways, different mutations, emerging KRAS-targeted therapies, and combination strategies. Finally, we discuss challenges associated with KRAS targeting and future directions, emphasizing pancreatic cancer.

Targeting KRAS: Crossroads of Signaling and Immune Inhibition

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

KRAS mutation: from undruggable to druggable in cancer

Unveiling the role of KRAS in tumor immune microenvironment

Targeting KRAS in Colorectal Cancer

Targeting KRAS in cancer

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Targeting KRAS G12C Mutations in Colorectal Cancer.

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Facts and hopes on RAS inhibitors and cancer immunotherapy

KRAS G12C inhibitor combination therapies: current evidence and challenge

Insights into Direct KRAS Inhibition Strategies for Cancer Treatment

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers